Update on gastric cancer treatments and gene therapies
- PMID: 31486976
- DOI: 10.1007/s10555-019-09803-7
Update on gastric cancer treatments and gene therapies
Abstract
Gastric cancer is an active topic of clinical and basic research due to high morbidity and mortality. To date, gastrectomy and chemotherapy are the only therapeutic options for gastric cancer patients, but drug resistance, either acquired or primary, is the main cause for treatment failure. Differences in development and response to cancer treatments have been observed among ethnically diverse GC patient populations. In spite of major incidence, GC Asian patients have a significantly better prognosis and response to treatments than Caucasian ones due to genetic discordances between the two populations. Gene therapy could be an alternative strategy to overcome such issues and especially CRISPR/Cas9 represents one of the most intriguing gene-editing system. Thus, in this review article, we want to provide an update on the currently used therapies for the treatment of advanced GC. Graphical abstract.
Keywords: CRISPR; Chemotherapy; Gastric cancer; Gene therapy; Metastases.
Similar articles
-
Adenoviral gene therapy in gastric cancer: a review.World J Gastroenterol. 2008 Jan 14;14(2):180-4. doi: 10.3748/wjg.14.180. World J Gastroenterol. 2008. PMID: 18186552 Free PMC article. Review.
-
Gene therapy for gastric cancer: a review.World J Gastroenterol. 2003 Nov;9(11):2390-4. doi: 10.3748/wjg.v9.i11.2390. World J Gastroenterol. 2003. PMID: 14606062 Free PMC article. Review.
-
Gene therapy for gastric cancer: problems and prospects.Surg Oncol. 2000 Jul;9(1):13-6. doi: 10.1016/s0960-7404(00)00017-7. Surg Oncol. 2000. PMID: 11525301 Review. No abstract available.
-
Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.Eur J Surg Oncol. 2018 May;44(5):613-619. doi: 10.1016/j.ejso.2018.02.004. Epub 2018 Feb 9. Eur J Surg Oncol. 2018. PMID: 29503129
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).BMC Cancer. 2019 May 6;19(1):420. doi: 10.1186/s12885-019-5640-2. BMC Cancer. 2019. PMID: 31060544 Free PMC article.
Cited by
-
Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer.Front Immunol. 2022 Jul 8;13:939836. doi: 10.3389/fimmu.2022.939836. eCollection 2022. Front Immunol. 2022. PMID: 35898512 Free PMC article.
-
Exploring the active ingredients of Banzhilian and its mechanism of action on diabetic Gastric cancer based on network pharmacology.Sci Rep. 2025 Apr 28;15(1):14808. doi: 10.1038/s41598-025-98214-6. Sci Rep. 2025. PMID: 40295613 Free PMC article.
-
Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5/PI3K/AKT/mTOR pathway in gastric cancer.Cancer Cell Int. 2022 Sep 23;22(1):290. doi: 10.1186/s12935-022-02717-5. Cancer Cell Int. 2022. PMID: 36151545 Free PMC article.
-
ALDH1: A potential therapeutic target for cancer stem cells in solid tumors.Front Oncol. 2022 Oct 28;12:1026278. doi: 10.3389/fonc.2022.1026278. eCollection 2022. Front Oncol. 2022. PMID: 36387165 Free PMC article. Review.
-
Exosomal CircPRRX1 Enhances Doxorubicin Resistance in Gastric Cancer by Regulating MiR-3064-5p/PTPN14 Signaling.Yonsei Med J. 2020 Sep;61(9):750-761. doi: 10.3349/ymj.2020.61.9.750. Yonsei Med J. 2020. PMID: 32882759 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous